GHRP-6 for Health & Longevity

Evidence Review created on 08/07/2026 using AI4L / Opus 5

Also known as: Growth Hormone-Releasing Peptide-6, Growth Hormone-Releasing Hexapeptide, GHRP6, Hexapeptide-2, SKF-110679, U-75799E, CIGB-500, His-D-Trp-Ala-Trp-D-Phe-Lys-NH2

Motivation

GHRP-6 (growth hormone-releasing peptide-6) is a small laboratory-made chain of six amino acids that prompts the pituitary gland to release a burst of the body’s own growth hormone. It works by imitating ghrelin, the stomach hormone that signals hunger, so it raises appetite alongside growth hormone. Because the body’s growth hormone output declines steadily from early adulthood onward, compounds that restore those pulses attract interest from people seeking to preserve muscle and tissue repair with age.

Built in the early 1980s as a laboratory probe, it was the compound that led researchers to the hunger hormone system itself. It was never approved as a treatment anywhere, yet it has had two very different afterlives: as a hospital test of pituitary function, and as a gray-market injectable sold online. A separate line of work in Cuba has instead pursued it as a tissue-protecting drug for the heart and brain.

This review examines what is known about GHRP-6 in people: how reliably it raises growth hormone, what it does to appetite, blood sugar, and stress hormones, what the tissue-protection work has and has not shown, and how far the circulating protocols, monitoring, and sourcing practices can be supported.

Benefits - Risks - Protocol - Conclusion

Grokipedia

GHRP-6

A structured reference entry covering the peptide’s chemistry, receptor pharmacology, development history, therapeutic research, non-medical use, safety profile, and legal status. It is the most comprehensive single-page summary available and is useful for orienting quickly before reading the primary literature.

Examine

No Examine.com article exists for GHRP-6. Examine.com’s database covers dietary supplements and food-derived compounds; it does not cover unapproved injectable peptides or prescription medications, which is the category GHRP-6 falls into.

ConsumerLab

No ConsumerLab.com article or product review exists for GHRP-6. ConsumerLab tests retail dietary supplements and consumer health products; it does not cover unapproved injectable peptides or prescription medications, so no entry for this compound would be expected.

Systematic Reviews

No systematic reviews or meta-analyses for GHRP-6 were found on PubMed as of August 7, 2026.

Mechanism of Action

GHRP-6 is a synthetic hexapeptide (a chain of six amino acids) with the sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH2. Two of its residues are D-amino acids, the mirror-image form that human enzymes cut slowly, which is what allows such a short peptide to survive in the bloodstream long enough to act.

Its primary target is GHS-R1a (growth hormone secretagogue receptor type 1a, the cell-surface docking site whose natural key is the hunger hormone ghrelin), which sits on the hypothalamus and the pituitary. Binding activates phospholipase C (an enzyme that generates second-messenger molecules inside the cell) and drives calcium influx into pituitary somatotroph cells, triggering release of stored GH (growth hormone, the pituitary hormone that drives tissue growth, repair, and fat mobilization). Circulating GH then acts on the liver to generate IGF-1 (insulin-like growth factor 1, the messenger through which most growth hormone effects on tissue are actually delivered).

Two-key amplification with the natural pathway: GHRP-6 works through a route separate from GHRH (growth hormone-releasing hormone, the brain signal that normally triggers growth hormone release), and it also suppresses somatostatin, the brake on that system. Giving both together produces a substantially larger pulse than either alone, which is why the combined provocative test became a clinical diagnostic (Micic et al., 1995).
A second, hormone-independent receptor: GHRP-6 also binds CD36, a fat-transport receptor found on heart muscle, immune cells, and wound granulation tissue (the new repair tissue that fills a healing wound). CD36 engagement activates the PI3K/AKT pathway (a cell-survival signaling cascade that blocks programmed cell death), reduces reactive oxygen species (unstable oxygen molecules that damage cell components), and activates PPAR-γ (peroxisome proliferator-activated receptor gamma, a gene switch governing fat handling and inflammation). This branch is proposed to explain the tissue-protective findings, which persist even where growth hormone release is not the relevant variable (Berlanga-Acosta et al., 2017).
Hypothalamic-pituitary-adrenal spillover: Unlike GHRH, GHRP-6 also drives release of ACTH (adrenocorticotropic hormone, the pituitary signal instructing the adrenal glands to make cortisol) and therefore raises cortisol. This is a receptor-level property of the ghrelin system, not an impurity effect (Frieboes et al., 1995).

Competing mechanistic interpretations. The case for GHRP-6 as a longevity-relevant compound rests on restoring a youthful pattern of pulsatile growth hormone secretion, with the argument that pulsatility — not total hormone exposure — is what tissues respond to, and that the pituitary of an older adult remains fully capable of producing young-adult pulses when correctly stimulated. The case against it rests on the opposite reading of the same axis: in mammals, reduced growth hormone signaling is one of the most reproducible interventions that extends lifespan, and humans with inherited growth hormone receptor deficiency show markedly lower rates of cancer and diabetes despite lifelong obesity (Guevara-Aguirre et al., 2011). On that view, deliberately raising growth hormone and IGF-1 output trades late-life tissue repair against the same signaling that is associated with faster biological aging. Separately, deleting ghrelin in mice prevents aging-associated obesity and muscle dysfunction without shortening life (Guillory et al., 2017), which argues that more ghrelin-receptor signaling is not self-evidently protective. Both readings are currently unresolved by human outcome data.

Key pharmacological properties. GHRP-6 is a peptide, not a small molecule, and its handling in the body reflects that:

Half-life: After intravenous dosing at 100–400 µg/kg in healthy men, disposition follows a two-compartment pattern with a distribution half-life of 7.6 ± 1.9 minutes and an elimination half-life of 2.5 ± 1.1 hours (Cabrales et al., 2013).
Selectivity: Selective for GHS-R1a and CD36. In the original human work it raised growth hormone without changing luteinizing hormone, follicle-stimulating hormone, thyroid-stimulating hormone, or ACTH at low doses; ACTH and cortisol effects emerge at higher or repeated doses.
Tissue distribution: Receptor expression concentrates in the hypothalamus and pituitary for the secretagogue effect, with CD36 expression in heart muscle, immune scavenger cells, liver cells, and granulation tissue accounting for the described tissue-protective actions.
Metabolism: Degraded by plasma and tissue peptidases (enzymes that cut peptide chains) into inactive fragments cleared by the kidney. It is not a substrate for the cytochrome P450 liver enzyme system that metabolizes most oral drugs, so classical CYP-mediated drug interactions do not apply.
Oral bioavailability: Effectively nil. In a direct comparison, 300 µg/kg given orally in enteric-coated capsules produced no change in growth hormone, whereas 30 µg/kg given intranasally did (Frieboes et al., 1999).

Historical Context & Evolution

Original intended use: GHRP-6 was designed by Cyril Bowers and colleagues in the early 1980s, from a series of opioid-peptide derivatives that unexpectedly released growth hormone in pituitary cell culture. It was the first such hexapeptide with confirmed activity in whole animals, and it was created as a laboratory probe for a then-unknown receptor, not as a therapy. SmithKline & French carried it into humans under the code SKF-110679, where a 30-minute infusion of 0.25–1.0 µg/kg produced a dose-dependent growth hormone rise with no change in other pituitary hormones (Ilson et al., 1989).
What the early findings actually showed: The 1980s and 1990s work established three things that have held up. GHRP-6 releases growth hormone through a pathway independent of GHRH; the two act synergistically when combined; and the response holds up in older adults whose response to GHRH has already fallen (Micic et al., 1995). The last finding was interpreted at the time as evidence that age-related growth hormone decline is functional and reversible rather than a permanent loss of pituitary capacity — an interpretation that remains defensible on the hormonal data and untested on health outcomes. It has not gone unchallenged: parallel work in cohorts aged 65–84 found the response to this peptide class clearly reduced relative to young adults (Arvat et al., 1994), so what survives is a smaller age-related fall than GHRH shows, not the absence of one.
Reverse pharmacology and the discovery of ghrelin: Because GHRP-6 clearly bound something, the search for its receptor led to the cloning of GHS-R1a in 1996, and the receptor in turn led to the isolation of its natural ligand, ghrelin, in 1999. GHRP-6’s most consequential scientific legacy is therefore the discovery of an entire hormone system, not any therapeutic result of its own.
Why it came to be considered for health optimization: Once ghrelin was identified, GHRP-6 was recognized as a stable ghrelin mimic that could be dosed. Three properties made it attractive outside the clinic: the growth hormone pulse it produces is endogenous and pulsatile rather than a flat exogenous infusion; the response fades with age far less than the natural brain signal does; and the peptide is cheap to synthesize. The same properties made it a fixture of the gray-market performance and physique market, where it circulated long before any of the clinical questions were settled.
Why development stalled, and what replaced it: Injectable GHRP-6 was not pursued as a growth hormone therapy, for reasons that were commercial and pharmaceutical rather than a refutation of its pharmacology. Recombinant human growth hormone was already approved and gave direct, titratable control; and orally active non-peptide secretagogues such as MK-677 were more attractive as products. GHRP-6 instead found a durable clinical role as a diagnostic agent, where the combined GHRH plus GHRP-6 test became a reproducible, well-validated measure of pituitary reserve (Popovic et al., 2004; Leal et al., 2002).
The Cuban tissue-protection program: From the 2000s, the Center for Genetic Engineering and Biotechnology (CIGB) in Havana pursued a completely different rationale — GHRP-6 as a cell-survival agent acting through CD36 rather than as a hormone-releasing agent. That program has produced the compound’s only late-stage human trial and has advanced it under the development code CIGB-500. This body of work is largely single-institution and the institution developing the product is also the source of nearly all of the supporting evidence, a conflict of interest that is discussed further in the Emerging Research and Conclusion sections.
How the picture has shifted: The current position is not that the early findings were overturned. The hormonal pharmacology has replicated consistently for nearly four decades. What changed is the evaluative frame: long-term trials of the oral class comparator showed that raising growth hormone and IGF-1 into the young-adult range produces measurable body-composition change without measurable functional gain, while human genetics work pointed toward lower growth hormone signaling as the pattern associated with reduced cancer and diabetes. Neither line settles the question for GHRP-6 specifically, and neither has been tested against a health-outcome endpoint in people using this peptide.

Expected Benefits

High 🟩 🟩 🟩

Acute, Dose-Dependent Release of Endogenous Growth Hormone

This is the effect GHRP-6 was built to produce and the only one demonstrated repeatedly and unambiguously in humans. The peptide binds GHS-R1a on pituitary somatotrophs and simultaneously suppresses somatostatin tone, releasing a discrete growth hormone pulse rather than a sustained elevation. The evidence base comprises the original dose-ranging human infusion study, dozens of subsequent provocative-testing studies in several hundred subjects, and its formal validation as a clinical diagnostic. The limitation is precise: what is established is the hormone pulse, not any downstream clinical benefit from repeatedly producing one.

Magnitude: Peak serum growth hormone rose from 17.8 ± 6.1 µg/L at 0.25 µg/kg to 38.3 ± 9.2 µg/L at 0.5 µg/kg and 63.0 ± 5.4 µg/L at 1.0 µg/kg intravenously, versus saline control (p = 0.002 at the top dose; p = the probability that a difference this large would appear by chance alone, with values below 0.05 conventionally treated as unlikely to be chance) (Ilson et al., 1989).

Medium 🟩 🟩

Retained Growth Hormone Response into Later Adulthood ⚠️ Conflicted

Most stimuli that release growth hormone lose potency with age, which is a central obstacle for anyone attempting to restore youthful pulses after midlife, and GHRP-6 is widely marketed as escaping it. The evidence is directly conflicted. In a controlled comparison of nine young adults against nine adults averaging 59.5 years, each of whom received all three stimuli, the response to GHRH fell significantly with age while the response to GHRP-6 alone, and to the combination, did not differ between the groups — which would place the age-related decline upstream of the pituitary, in hypothalamic signaling, rather than in the somatotroph’s capacity to secrete. Work in genuinely elderly cohorts points the other way: the growth hormone output after the closely related peptide hexarelin was less than half as large in adults aged 65–84 as in adults aged 24–30, and adding GHRH narrowed but did not close that gap (Arvat et al., 1994). The most defensible reading is that the response falls with age far less than the natural brain signal does, but does not stay flat, and that the 59.5-year cohort was too young to test the question at the older end of the target range.

Magnitude: Growth hormone responses to 90 µg intravenous GHRP-6 did not differ between adults aged 22 ± 1.1 years and 59.5 ± 1.7 years (p = not significant), whereas responses to GHRH alone were significantly lower in the older group (p = 0.03) (Micic et al., 1995); against this, the growth hormone area under the curve (the total hormone exposure accumulated over the measurement window, rather than the single highest reading) after intravenous hexarelin was 2112 ± 683 µg·min/L in adults aged 65–84 versus 4849 ± 601 µg·min/L in adults aged 24–30 (p < 0.001) (Arvat et al., 1994).

Stimulation of Appetite and Food Intake

GHRP-6 is the most strongly orexigenic (appetite-stimulating) of the clinically studied growth hormone-releasing peptides, a direct consequence of its ghrelin mimicry at hypothalamic feeding centers. For the great majority of health- and longevity-oriented adults this is an unwanted effect and it appears again in the Risks section; it is listed here because for the narrow subset deliberately pursuing mass gain, or managing appetite loss during aggressive training blocks or illness recovery, it is the intended effect of the compound. The evidence is consistent across animal models, human ghrelin-infusion work, and the clinical development of related ghrelin-receptor agonists for cachexia (the severe muscle and weight loss driven by chronic illness), but no controlled human study has quantified food intake under GHRP-6 specifically.

Magnitude: In the closest long-term human comparator — the oral ghrelin-receptor agonist MK-677 at 25 mg daily for 12 months in adults aged 60–81 — increased appetite was the most frequent effect reported and body weight rose 2.7 kg (95% CI 2.0 to 3.5; CI = confidence interval, the range within which the true value most likely falls) versus 0.8 kg (95% CI −0.3 to 1.8) on placebo (p = 0.003) (Nass et al., 2008).

Low 🟩

Preservation of Lean Mass Under Catabolic Stress

The proposed benefit is that a restored growth hormone pulse shifts nitrogen balance toward tissue building, protecting muscle during caloric restriction, illness, or age-related loss. Direct human evidence for GHRP-6 does not exist; the supporting data come from the oral class comparator MK-677, where a 2-year randomized placebo-controlled trial in 65 healthy older adults showed a real gain in fat-free mass, and a shorter study showed reversal of diet-induced nitrogen loss (Murphy et al., 1998). The critical qualifier is that the same trial found no accompanying change in isokinetic strength (strength measured on a machine that holds the movement to a fixed speed), physical function, or quality of life, and that abdominal visceral fat did not fall. Extrapolating from an oral non-peptide with a 24-hour action profile to an injected peptide with a 2.5-hour half-life is an assumption, not a finding.

Magnitude: Fat-free mass changed by +1.1 kg (95% CI 0.7 to 1.5) on the class comparator versus −0.5 kg (95% CI −1.1 to 0.2) on placebo over 12 months (p < 0.001), with no change in strength or function (Nass et al., 2008).

Modest Increase in Light Sleep ⚠️ Conflicted

Repeated night-time intravenous boluses in healthy men increased stage 2 sleep, the light non-dreaming stage that occupies roughly half the night. The evidence is directly conflicted on two counts. First, the benefit did not extend to slow-wave sleep, the deep stage most associated with recovery and with the natural nocturnal growth hormone pulse, which was unchanged — whereas GHRH increases slow-wave sleep. Second, a follow-up study comparing routes found the effect reversed by administration route: oral dosing decreased stage 2 sleep in the second half of the night, sublingual dosing did nothing measurable, and intranasal dosing showed only a non-significant trend with a fall in delta power (the electrical measure of how deep and intense slow-wave sleep is) (Frieboes et al., 1999). The same intravenous protocol that increased stage 2 sleep also roughly doubled nocturnal cortisol, so the sleep signal cannot be read as clean.

Magnitude: Stage 2 sleep 270.1 ± 25.3 minutes after 4 × 50 µg intravenous boluses versus 245.4 ± 25.8 minutes on placebo (p < 0.02), a difference of about 25 minutes; slow-wave sleep unchanged (Frieboes et al., 1995).

Reduced Disability After Severe Ischemic Stroke ⚠️ Conflicted

A multicenter open-label phase III trial gave intravenous epidermal growth factor plus GHRP-6 twice daily for 7 days to patients within 12 hours of ischemic stroke onset. The evidence is directly conflicted: across the full enrolled population the combination produced no benefit on disability, function, or survival, so the trial failed on its stated primary endpoint. In the small pre-specified severe-stroke subgroup, disability and mortality were both lower and infarct volume shrank more in the affected territory. A subgroup finding of this size, in an open-label trial, from the sponsor that developed the compound, is hypothesis-generating rather than confirmatory, and the peptide was given in combination so its individual contribution cannot be separated (Hernández-Bernal et al., 2026).

Magnitude: In the severe-stroke subgroup (n = 27), 6-month modified Rankin Scale score (the standard 0-to-6 stroke disability scale, on which a lower number means less disability) 2.6 (95% CI 1.3 to 3.8) with treatment versus 4.7 (95% CI 2.6 to 6.0) with standard care (p = 0.03), and a mortality hazard ratio (the relative rate of an event between two groups) of 0.18 (95% CI 0.03 to 0.96, p = 0.045); no difference in the full population of 188.

Speculative 🟨

Cardioprotection After Ischemic or Toxic Myocardial Injury

The claim is that CD36 engagement activates survival signaling in cardiomyocytes, limiting cell death and the fibrotic scarring that follows injury. Preclinical support is substantial and mechanistically coherent: in permanent coronary ligation in rats, GHRP-6 reduced interstitial fibrosis and preserved left ventricular systolic function, with proteomic analysis (a broad survey of which proteins a tissue is producing) showing upregulation of fatty acid oxidation, antioxidant defense, and anti-apoptotic pathways (Wang et al., 2026); given alongside the chemotherapy agent doxorubicin, it prevented ventricular dilation and preserved mitochondrial integrity (Berlanga-Acosta et al., 2024). No human cardiac outcome trial of any size has been run, so the basis remains animal work only, and essentially all of it originates from one institution, the Center for Genetic Engineering and Biotechnology in Havana, which develops and holds the rights to the compound.

Accelerated Wound Closure and Reduced Hypertrophic Scarring

Topical GHRP-6 in a gel base accelerated closure of full-thickness excisional wounds in rats and sharply reduced the formation of raised hypertrophic scars in the standard rabbit-ear model, apparently by activating PPAR-γ and dampening fibrogenic signaling in granulation tissue. No controlled human studies exist; the basis is entirely animal work from a single group, and the same experiments showed no effect at all on already-consolidated scars (Mendoza Marí et al., 2016).

Cytoprotection of Liver, Gut, Lung, and Kidney

Rodent work reports that GHRP-6 attenuates acute lung injury and its progression to interstitial fibrosis (Wang et al., 2026), and that a GHRP-6 hydrogel limits acute kidney injury through metabolic reprogramming (Zhao et al., 2025). The same protection extends to the liver and the gut: pre-treatment in a liver ischemia-reperfusion model of multiple organ failure (ischemia-reperfusion injury is the damage done when blood flow returns to a tissue that was starved of it) cut liver and intestinal damage, immune-cell infiltration, and lipid peroxidation (oxidative damage to cell membranes) by 50–85%, with lung and kidney injury reduced alongside (Cibrián et al., 2006), and reduction of liver fibrotic scarring is the finding the wound-healing work was built on. Gastric erosions induced by immersion-restraint stress were likewise prevented by prior peripheral dosing (Guo et al., 2012). The proposed mechanism is CD36-mediated suppression of fibrogenic cytokines and activation of cell-survival signaling, the same pathway implicated in the cardiac and wound findings. The basis is mechanistic and preclinical only, with no controlled human data in any organ system.

Mitochondrial and Antioxidant Support Relevant to Biological Aging

Proteomic analyses in treated animals show coordinated upregulation of fatty acid beta-oxidation, antioxidant defense, and mitochondrial metabolic reprogramming, and the broader ghrelin literature describes the hormone as an endogenous antioxidant and protective agent. Whether any of this translates into slowed biological aging in humans is entirely untested; the basis is mechanistic inference from animal proteomics and from the parent hormone’s biology, with no controlled human studies of GHRP-6 on any aging biomarker.

Bone Formation and Preservation of Bone Mineral Density

Growth hormone and IGF-1 are anabolic to bone, driving the bone-formation side of the remodeling cycle, so a restored pulse is proposed to slow age-related bone loss alongside its effect on muscle. The human basis is entirely class-level: the 2-year oral class-comparator trial reported changes in bone mineral density consistent with increased bone remodeling rather than a demonstrated net density gain (Nass et al., 2008), and a completed phase I trial of another ghrelin-receptor agonist carried a bone-formation marker only as a secondary endpoint (NCT04021706). Because faster remodeling transiently lowers density before any gain can appear, the direction of the long-term effect is unresolved. No controlled study of GHRP-6 has measured bone density, bone turnover, or fracture rate in people, so the basis here is mechanistic inference plus class-level biomarker movement only.

Benefit-Modifying Factors

Adiposity and body mass index: Body fat is the single largest modifier of the growth hormone response. In 542 subjects tested with the combined GHRH plus GHRP-6 protocol, adiposity correlated negatively with the growth hormone peak (r = −0.503; r = correlation coefficient, a measure from −1 to +1 of how tightly two variables move together, p < 0.0001) and accounted for roughly 25% of the reduction in release; above a body mass index of 35 (BMI, weight relative to height), the diagnostic thresholds had to be lowered by 5 µg/L to remain valid (Kelestimur et al., 2006). A person carrying substantial excess fat gets a materially smaller pulse from the same dose.
Baseline IGF-1 and growth hormone status: Someone already in the upper part of the age-adjusted IGF-1 range has less headroom and less plausible benefit than someone in the lower quartile, while gaining the same downstream exposure risk. Baseline IGF-1, IGF binding protein 3 (the main carrier protein that holds IGF-1 in circulation), and fasting insulin define whether there is a deficit to correct at all.
Nutritional and fasting state: Growth hormone release through this pathway is strongly state-dependent. Fasting amplifies endogenous ghrelin-driven secretion (Muller et al., 2002), whereas elevated circulating free fatty acids and insulin from a recent meal blunt the pulse. The same dose delivers different results depending on when it is given relative to food.
Genetic variation in the receptor system: Polymorphisms in GHSR (the gene encoding the ghrelin receptor, which determines how strongly the docking site responds) and in CD36 (the gene for the fat-transport receptor that carries the tissue-protective signal) plausibly alter both branches of the response. Variants in GHRHR (the receptor for the natural brain signal) would modify the synergy seen with combination protocols. None of these has been validated as a predictor of response to GHRP-6 in a clinical study, so this remains a mechanistically grounded expectation rather than an actionable test.
Sex-based differences: Women secrete growth hormone with higher pulse amplitude and greater overall daily output than men at equivalent age, and generally show larger responses to secretagogue stimulation. Working against this, oral estrogen reduces the liver’s IGF-1 output for any given growth hormone level through a first-pass effect (the liver processes an oral dose before it reaches the rest of the body) that transdermal estrogen does not produce — so a woman on oral hormone therapy may see a strong hormone pulse with a muted downstream signal.
Pre-existing endocrine conditions: Thyroid status alters the response substantially, with untreated hyperthyroidism changing both growth hormone and ACTH answers to GHRP-6 (Molica et al., 2010). Hypercortisolism (persistently elevated cortisol) from any cause, including exogenous glucocorticoids, blunts the growth hormone response markedly. Poorly controlled type 2 diabetes and hepatic impairment both reduce IGF-1 generation for a given hormone pulse.
Age-related considerations: GHRP-6 is unusual in how well its efficacy holds up into later adulthood — the growth hormone response at roughly 60 years of age matched that of adults in their early twenties, whereas the response to GHRH did not (Micic et al., 1995). This advantage over GHRH is not the same as age-independence, and it should not be over-read at the oldest end of the target range: in cohorts aged 65–84 the response to this peptide class was less than half that of young adults (Arvat et al., 1994), so someone in their seventies should expect a smaller pulse per dose than someone in their fifties. The further countervailing point is that the older adults in whom the class has been studied longest gained lean mass without gaining strength or function, so preserved hormonal efficacy did not translate into preserved functional benefit.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Marked Appetite Stimulation and Unintended Weight Gain

GHRP-6 activates the same hypothalamic circuit that ghrelin uses to signal hunger, and it does so more strongly than any other peptide in its class. Users consistently describe intense hunger beginning 20–30 minutes after injection and lasting one to two hours. For a health- and longevity-oriented adult holding body composition deliberately, this is the dominant practical liability of the compound, because the weight gained under a ghrelin-receptor agonist is not selectively lean: in the long-term class comparator, limb fat rose more than four times as much on drug as on placebo. Appetite stimulation attenuated over several months in that trial but did not disappear.

Magnitude: Body weight rose 2.7 kg versus 0.8 kg on placebo over 12 months with the oral class comparator, and limb fat rose 1.1 kg versus 0.24 kg (p = 0.001), with no reduction in abdominal visceral fat (Nass et al., 2008).

Activation of the Stress-Hormone Axis

GHRP-6 releases ACTH and cortisol in addition to growth hormone, a property GHRH does not share and which is intrinsic to ghrelin-receptor agonism rather than a contaminant effect. In healthy men given repeated night-time boluses, nocturnal cortisol roughly doubled — precisely during the window when cortisol should be at its daily nadir and when it most directly opposes overnight recovery, glucose control, and immune function. Elevated cortisol is also the mechanism most likely to negate the body-composition effect the compound is taken for. The effect is dose- and route-dependent: oral dosing produced no change in ACTH or cortisol, and intranasal dosing produced only a non-significant trend toward higher ACTH with cortisol unchanged (Frieboes et al., 1999).

Magnitude: Nocturnal cortisol 56.0 ± 31.0 ng/mL after 4 × 50 µg intravenous boluses versus 25.2 ± 9.0 ng/mL on placebo (p < 0.02), with ACTH 21.0 ± 5.3 pg/mL versus 16.6 ± 3.1 pg/mL (p < 0.02) (Frieboes et al., 1995).

Reduced Insulin Sensitivity and Rising Fasting Glucose

Growth hormone is directly counter-regulatory to insulin, and sustained elevation predictably worsens glucose handling. Two independent lines of human evidence converge here. In the 12-month class-comparator trial, fasting glucose rose and measured insulin sensitivity fell. Separately, an experiment that blocked the growth hormone receptor with pegvisomant while giving GHRP-6 unmasked a rapid, tissue-specific insulin resistance in liver and muscle, showing that the peptide can degrade glucose control through routes that are not simply downstream of growth hormone (Muller et al., 2001). For an audience whose central longevity metrics include fasting insulin and metabolic flexibility, this is a direct trade against the intended benefit.

Magnitude: Fasting glucose rose an average of 0.3 mmol/L (5 mg/dL, p = 0.015) with reduced insulin sensitivity over 12 months on the class comparator (Nass et al., 2008); acutely under growth hormone receptor blockade, GHRP-6 raised serum insulin from 10.3 ± 2.1 to 81.3 ± 25.4 mU/L (p < 0.001) and glucose from 4.2 ± 0.3 to 6.0 ± 0.6 mmol/L (p < 0.05) (Muller et al., 2001).

Medium 🟥 🟥

Fluid Retention, Peripheral Edema, and Nerve Compression Symptoms

Growth hormone promotes sodium and water retention through effects on the kidney and the renin-angiotensin-aldosterone system (the hormone cascade that governs salt and water balance and blood pressure), and the resulting extracellular fluid expansion is the classic dose-limiting effect of every agent that raises growth hormone. It presents as ankle swelling, morning puffiness, joint aching, and — where fluid accumulates in confined anatomical spaces such as the carpal tunnel — as numbness and tingling in the hands. In the 2-year class-comparator trial, transient mild lower-extremity edema and muscle pain were among the most frequent adverse effects. Severity tracks dose closely and symptoms reverse on dose reduction or cessation, which distinguishes this from the irreversible soft-tissue changes of chronic pathological growth hormone excess.